Microbial Peptide Modules for Mucin Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for analyzing and targeting mucins are limited by the difficulty in isolating and understanding the complex glycosylation patterns of mucins, which are essential for binding microbial adhesins and therapeutic delivery, due to their large size, heterogeneity, and resistance to conventional glycoproteomics strategies.
Innovation Solution
Development of microbial peptide modules that selectively bind to densely O-glycosylated mucins, particularly in the tandem repeat regions, enabling targeted binding and delivery of therapeutic agents to mucosal surfaces with high affinity and precision.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional glycoproteomics strategies are used to analyze mucins, then standard proteomic methods can be applied, but the analysis fails due to the large size, heterogeneity, and resistance of mucins to these methods
Solution Approach 1:
The patent extracts the binding function from whole microbial adhesins and isolates the specific peptide module (X409) that is responsible for mucin binding. This extracted peptide module can then be used independently for targeted mucin analysis and binding, bypassing the limitations of conventional glycoproteomics methods that struggle with the complexity and heterogeneity of full mucin proteins.
Solution Approach 2:
The patent changes the scale and complexity parameter by using a small peptide module (21 amino acids) instead of large, heterogeneous mucin proteins or complex microbial adhesins. This parameter change from macromolecular complexity to simple peptide structure enables the use of standard analytical methods while maintaining specific binding capability.
2Reliability
If microbial adhesins are used to target mucins, then binding capability is achieved, but selectivity is reduced due to binding of simple oligosaccharides
Solution Approach 1:
The patent extracts only the specific peptide module (X409) from the full microbial adhesin that is responsible for selective mucin binding. This extracted module maintains the ability to bind densely O-glycosylated mucins while losing the ability to bind simple oligosaccharides, thereby achieving both selectivity and specificity.
Solution Approach 2:
The patent applies local quality by having the X409 peptide module bind specifically to the tandem repeat regions of mucins that contain dense O-glycan clusters. This localized binding to specific structural features (tandem repeats with O-glycan clusters) provides high selectivity for mucins while avoiding non-specific binding to simple oligosaccharides.
3Quantity of substance
If full coding expression constructs for mucins are produced by recombinant expression, then mucin production is achieved, but heterogeneous products result due to difficulties with assembly
Solution Approach 1:
Instead of attempting to produce full-length, heterogeneous mucin proteins through recombinant expression, the patent segments the problem by using a small, well-defined peptide module (X409) that binds to mucins. This segmentation allows for precise production of a homogeneous binding agent that can then interact with the heterogeneous mucin targets in vivo, avoiding the manufacturing precision problems of producing homogeneous full-length mucins.
4Object-affected harmful factors
If mucin layers are present to protect mucosal surfaces, then protection is achieved, but delivery of therapeutics through mucosal surfaces is obstructed
Solution Approach 1:
The patent uses the X409 peptide module as an intermediary that can bind to mucin layers and potentially facilitate therapeutic delivery. By attaching the payload to X409, the therapeutic agent gains the ability to interact with and potentially traverse the mucin barrier through the specific binding interface, while the mucin layer maintains its protective function for non-specific substances.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The microbial peptide modules achieve high selectivity and affinity for mucins like MUC5AC, allowing for precise delivery of payloads to intended tissues while minimizing off-target binding, thereby enhancing therapeutic efficacy and diagnostic capabilities.
Implementation Method 1
microbial peptide modules that selectively bind to densely O-glycosylated mucins, particularly in the tandem repeat regions, enabling targeted binding and delivery of therapeutic agents to mucosal surfaces with high affinity and precision
Data Source
AI summary
There are provided compositions and mucin-binding targeting agents derived from microbial proteins that have selective binding properties for densely glycosylated mucins as well as such compositions and targeting agents comprising a binding moiety and/or a pay load which may be attached to the binding moiety or directly to a targeting agent. The compositions and targeting agents may be used as medicaments in the treatment of a disease, illness, or disorders.